$RNA
Avidity Biosciences, Inc. Stock $rna

$rna Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000156459022008049 Filed on March 01, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$1.795M	$1.852M	$9.326M
YoY Change	-33.62%	-13.54%	37.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.567M	$7.431M	$26.20M
YoY Change	45.7%	54.17%	94.61%
% of Gross Profit
Research & Development	$27.69M	$32.97M	$101.2M
YoY Change	33.91%	142.06%	169.09%
% of Gross Profit
Depreciation & Amortization	$300.0K	$208.0K	$600.0K
YoY Change	200.0%	89.09%	50.0%
% of Gross Profit
Operating Expenses	$36.26M	$40.40M	$127.4M
YoY Change	36.5%	119.14%	149.45%
Operating Profit	-$34.46M		-$118.1M
YoY Change	44.44%		166.62%
Interest Expense	$250.0K	$55.00K	$104.0K
YoY Change		175.0%	-50.24%
% of Operating Profit
Other Income/Expense, Net	-$25.00K	-$46.00K	-$62.00K
YoY Change	-292.31%	-355.56%	-20.51%
Pretax Income	-$34.24M	-$38.54M	-$118.0M
YoY Change	43.6%	136.72%	166.03%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$34.24M	-$38.54M	-$118.0M
YoY Change	43.58%	136.79%	166.06%
Net Earnings / Revenue	-1907.24%	-2080.89%	-1265.38%
Basic Earnings Per Share	-$0.71		-$2.85
Diluted Earnings Per Share	-$709.6K	-$815.1K	-$2.849M
COMMON SHARES
Basic Shares Outstanding	47.75M		41.43M shares
Diluted Shares Outstanding	48.25M shares		41.43M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$397.1M	$405.5M	$405.5M
YoY Change	28.96%	23.6%	23.6%
Cash & Equivalents	$139.3M	$320.4M	$320.4M
Short-Term Investments	$257.8M	$85.10M	$85.10M
Other Short-Term Assets	$7.729M	$5.598M	$5.598M
YoY Change	93.23%	59.94%	59.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$404.8M	$411.1M	$411.1M
YoY Change	29.76%	23.96%	23.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.029M	$4.805M	$15.59M
YoY Change	129.95%	227.32%	720.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.049M	$599.0K	$850.0K
YoY Change	188.19%	1174.47%	183.33%
Total Long-Term Assets	$16.34M	$16.44M	$16.44M
YoY Change	482.98%	640.5%	647.23%
TOTAL ASSETS
Total Short-Term Assets	$404.8M	$411.1M	$411.1M
Total Long-Term Assets	$16.34M	$16.44M	$16.44M
Total Assets	$421.1M	$427.6M	$427.6M
YoY Change	33.8%	28.06%	28.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.82M	$14.09M	$14.09M
YoY Change	80.97%	82.92%	82.92%
Accrued Expenses	$6.785M	$10.71M	$10.71M
YoY Change	151.3%	234.66%	234.66%
Deferred Revenue		$4.864M
YoY Change		31.82%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.92M	$29.66M	$29.66M
YoY Change	76.69%	103.32%	103.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.51M	$16.49M	$16.49M
YoY Change	30.69%	25.89%	25.89%
Total Long-Term Liabilities	$14.51M	$16.49M	$16.49M
YoY Change	30.69%	25.89%	25.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.92M	$29.66M	$29.66M
Total Long-Term Liabilities	$14.51M	$16.49M	$16.49M
Total Liabilities	$45.43M	$46.15M	$46.15M
YoY Change	58.64%	66.76%	66.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$218.8M	-$184.5M
YoY Change	142.04%	177.28%
Common Stock	$596.5M	$566.2M
YoY Change	58.44%	51.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$375.7M	$381.4M	$381.4M
YoY Change
Total Liabilities & Shareholders Equity	$421.1M	$427.6M	$427.6M
YoY Change	33.8%	28.06%	28.06%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$34.24M	-$38.54M	-$118.0M
YoY Change	43.58%	136.79%	166.06%
Depreciation, Depletion And Amortization	$300.0K	$208.0K	$600.0K
YoY Change	200.0%	89.09%	50.0%
Cash From Operating Activities	-$29.57M	-$26.22M	-$94.81M
YoY Change	50.27%	100.42%	155.44%
INVESTING ACTIVITIES
Capital Expenditures	$758.0K	-$1.707M	$3.740M
YoY Change	44.38%	642.17%	242.49%
Acquisitions
YoY Change
Other Investing Activities	-$174.7M	-$82.36M	-$78.78M
YoY Change		1131.05%	1077.53%
Cash From Investing Activities	-$175.5M	-$84.06M	-$82.52M
YoY Change	33323.81%	1113.04%	959.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.10M		$19.60M
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	24.11M	20.71M	176.3M
YoY Change	141741.18%	4503.11%	-35.19%
NET CHANGE
Cash From Operating Activities	-29.57M	-26.22M	-94.81M
Cash From Investing Activities	-175.5M	-84.06M	-82.52M
Cash From Financing Activities	24.11M	20.71M	176.3M
Net Change In Cash	-175.5M	-89.57M	-1.014M
YoY Change	769.16%	357.9%	-100.45%
FREE CASH FLOW
Cash From Operating Activities	-$29.57M	-$26.22M	-$94.81M
Capital Expenditures	$758.0K	-$1.707M	$3.740M
Free Cash Flow	-$30.33M	-$24.51M	-$98.55M
YoY Change	50.11%	90.72%	157.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.005
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.015
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.027
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	rna	Net Income Loss To Date Of Conversion NetIncomeLossToDateOfConversion	-2549000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3690000
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021Q2	dei	Entity Public Float EntityPublicFloat	798100000
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	320448000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	321462000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	85095000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6679000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	5598000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3537000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	411141000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	331678000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4805000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1468000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	251000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	251000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10784000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	454000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	599000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47000
CY2021Q4	us-gaap	Assets Assets	427580000
CY2020Q4	us-gaap	Assets Assets	333898000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14085000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7745000
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	8940000
CY2020Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3152000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1769000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4864000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29658000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14587000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9960000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	938000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6532000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12150000
CY2021Q4	us-gaap	Liabilities Liabilities	46150000
CY2020Q4	us-gaap	Liabilities Liabilities	27675000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47754000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-118191000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44360000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24734000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.85
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.12
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47754000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37569000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37569000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	566161000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	372764000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-187000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-184549000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66540000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	381430000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	306223000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	427580000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	333898000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9326000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6787000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101182000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37602000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26195000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13462000
CY2021	us-gaap	Operating Expenses OperatingExpenses	127377000
CY2020	us-gaap	Operating Expenses OperatingExpenses	51064000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-118051000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-44277000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	104000
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	206000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-118009000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-182000
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41428000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21663000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2713000
CY2018Q4	us-gaap	Members Equity MembersEquity	-41129000
CY2019	rna	Partners Capital Units Issued During Period Value Unit Options Exercised PartnersCapitalUnitsIssuedDuringPeriodValueUnitOptionsExercised	38000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4683000
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2800000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4310000
CY2019	rna	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	-80000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	17056000
CY2019	rna	Stock Issued During Period Value Stock Options Exercised Net Of Repurchases StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases	26000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	36000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	389000
CY2019	rna	Net Income Loss Excluding Conversion NetIncomeLossExcludingConversion	-22185000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-65357000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	136920000
CY2020	rna	Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering	120000
CY2020	rna	Stock Issued During Period Value Stock Options Exercised Net Of Repurchases StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases	22000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	444000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	70000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4310000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-44355000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	306223000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	930000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	709000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17056000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-118009000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-182000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	381430000
CY2021	us-gaap	Profit Loss ProfitLoss	-118009000
CY2020	us-gaap	Profit Loss ProfitLoss	-44355000
CY2019	us-gaap	Profit Loss ProfitLoss	-24734000
CY2021	us-gaap	Depreciation Depreciation	639000
CY2020	us-gaap	Depreciation Depreciation	373000
CY2019	us-gaap	Depreciation Depreciation	348000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	406000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-179000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	29000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	71000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	16000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	rna	Noncash Interest Expense NoncashInterestExpense	0
CY2020	rna	Noncash Interest Expense NoncashInterestExpense	110000
CY2019	rna	Noncash Interest Expense NoncashInterestExpense	7027000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	75000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2510000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2444000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	949000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6043000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5749000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	436000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5788000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1838000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1010000
CY2021	rna	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	461000
CY2020	rna	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	289000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	709000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4444000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3100000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	18940000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2021	rna	Distributions To Members DistributionsToMembers	0
CY2020	rna	Distributions To Members DistributionsToMembers	0
CY2019	rna	Distributions To Members DistributionsToMembers	-106000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11262000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	24026000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	930000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	65000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-94813000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37117000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2490000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	85357000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6693000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6580000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3740000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1092000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82517000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7785000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-235000
CY2021	rna	Proceeds From Issuance Of Common Stock In Public Offering Gross ProceedsFromIssuanceOfCommonStockInPublicOfferingGross	185939000
CY2020	rna	Proceeds From Issuance Of Common Stock In Public Offering Gross ProceedsFromIssuanceOfCommonStockInPublicOfferingGross	298080000
CY2019	rna	Proceeds From Issuance Of Common Stock In Public Offering Gross ProceedsFromIssuanceOfCommonStockInPublicOfferingGross	0
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	2200000
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	72623000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	19451000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	176316000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	272037000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89233000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1014000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	227135000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	91488000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	321713000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94578000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3090000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	320699000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	321713000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94578000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2020	us-gaap	Interest Paid Net InterestPaidNet	571000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	322000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12074000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	936000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	807000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	220000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	118000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	43000
CY2021Q4	us-gaap	Change In Accounting Principle Accounting Standards Update Adoption Date ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate	2019-01-01
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0
CY2020	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	136920000
CY2019	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0
CY2021	rna	Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes	0
CY2020	rna	Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes	0
CY2019	rna	Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes	29510000
CY2021	rna	Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering	0
CY2020	rna	Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering	120000
CY2019	rna	Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering	0
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split).
CY2020Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2.1095
CY2021Q3	rna	Sale Of Common Stock Maximum Aggregate Offering Price SaleOfCommonStockMaximumAggregateOfferingPrice	150000000.0
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	780549000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19600000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-184500000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	405500000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial statements<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP, which</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> the Company </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements </span>relate <span style="letter-spacing:0.1pt;">to</span> revenue recognition, stock-based compensation, and accrued research and development costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company’s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p>
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.</p>
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	33600
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	123285
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	217524
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5796000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3858000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19545000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2774000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	85282000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	187000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	85095000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6684000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6679000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6538000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11729000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3447000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1733000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1979000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4805000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1468000
CY2021	us-gaap	Depreciation Depreciation	600000
CY2020	us-gaap	Depreciation Depreciation	400000
CY2019	us-gaap	Depreciation Depreciation	300000
CY2021	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	During the periods presented, the Company was party to various non-cancellable office and laboratory space operating leases and short-term leases. Currently, the Company is only party to a non-cancellable office and laboratory space operating lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10784000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9960000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1769000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3113000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3207000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3303000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3111000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14503000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.23
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.42
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1769000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9960000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	163000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	382000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	302000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2021Q3	rna	Sale Of Common Stock Maximum Aggregate Offering Price SaleOfCommonStockMaximumAggregateOfferingPrice	150000000.0
CY2021Q3	rna	Termination Notice Period For Sales Agreement TerminationNoticePeriodForSalesAgreement	P10D
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	780549000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19600000
CY2019Q2	rna	Retained Earnings Accumulated Deficit Reclassified To Additional Paid In Capital RetainedEarningsAccumulatedDeficitReclassifiedToAdditionalPaidInCapital	44100000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3788000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.06
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2671000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	509000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.99
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5778000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.49
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58950000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	29226000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1057000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.91
CY2021	rna	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	210000
CY2020	rna	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	1000
CY2019	rna	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	14000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5778000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	14.49
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	58950000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1885000
CY2021	rna	Income Tax Reconciliation Book Income Loss For Pre Conversion Period IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod	0
CY2020	rna	Income Tax Reconciliation Book Income Loss For Pre Conversion Period IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3400000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24784000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9315000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5194000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7868000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3004000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.78
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.63
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.46
CY2021Q4	rna	Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised	15288
CY2020Q4	rna	Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised	69359
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17056000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4310000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	406000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8992000
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6936000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	rna	Income Tax Reconciliation Book Income Loss For Pre Conversion Period IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod	527000
CY2021	rna	Income Tax Reconciliation Interest On Convertible Notes IncomeTaxReconciliationInterestOnConvertibleNotes	0
CY2020Q4	rna	Deferred Tax Assets Intangibles And Fixed Assets DeferredTaxAssetsIntangiblesAndFixedAssets	2483000
CY2021Q4	rna	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3291000
CY2020Q4	rna	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	263000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	477000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	153000
CY2021Q4	rna	Deferred Tax Assets Intangibles And Fixed Assets DeferredTaxAssetsIntangiblesAndFixedAssets	2137000
CY2020	rna	Income Tax Reconciliation Interest On Convertible Notes IncomeTaxReconciliationInterestOnConvertibleNotes	0
CY2019	rna	Income Tax Reconciliation Interest On Convertible Notes IncomeTaxReconciliationInterestOnConvertibleNotes	445000
CY2021	rna	Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes	0
CY2020	rna	Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes	0
CY2019	rna	Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes	958000
CY2021	rna	Income Tax Reconciliation Reserve For Uncertain Tax Positions IncomeTaxReconciliationReserveForUncertainTaxPositions	1170000
CY2020	rna	Income Tax Reconciliation Reserve For Uncertain Tax Positions IncomeTaxReconciliationReserveForUncertainTaxPositions	398000
CY2019	rna	Income Tax Reconciliation Reserve For Uncertain Tax Positions IncomeTaxReconciliationReserveForUncertainTaxPositions	140000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4792000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1639000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	584000
CY2021	rna	Income Tax Reconciliation Deferred Tax Recognized Upon Conversion IncomeTaxReconciliationDeferredTaxRecognizedUponConversion	0
CY2020	rna	Income Tax Reconciliation Deferred Tax Recognized Upon Conversion IncomeTaxReconciliationDeferredTaxRecognizedUponConversion	0
CY2019	rna	Income Tax Reconciliation Deferred Tax Recognized Upon Conversion IncomeTaxReconciliationDeferredTaxRecognizedUponConversion	3076000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35326000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13488000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7827000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	738000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	71000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41443000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11277000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5586000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1855000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3117000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4443000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3668000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	969000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59719000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21443000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56693000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21316000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3026000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	127000
CY2021Q4	rna	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3026000
CY2020Q4	rna	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	127000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3026000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	127000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	35400000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13500000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	671000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	156000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1283000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	446000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	42000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	62000
CY2021	rna	Unrecognized Tax Benefits Other True Up Adjustment UnrecognizedTaxBenefitsOtherTrueUpAdjustment	0
CY2020	rna	Unrecognized Tax Benefits Other True Up Adjustment UnrecognizedTaxBenefitsOtherTrueUpAdjustment	7000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1996000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	671000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0

Files In Submission

Name	View Source	Status
R5.htm	Edgar Link	pending
0001564590-22-008049-index-headers.html	Edgar Link	pending
0001564590-22-008049-index.html	Edgar Link	pending
0001564590-22-008049.txt	Edgar Link	pending
0001564590-22-008049-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gsua0c5v34oe000001.jpg	Edgar Link	pending
gsua0c5v34oe000002.jpg	Edgar Link	pending
gsua0c5v34oe000003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rna-10k_20211231.htm	Edgar Link	pending
rna-10k_20211231_htm.xml	Edgar Link	completed
rna-20211231.xsd	Edgar Link	pending
rna-20211231_cal.xml	Edgar Link	unprocessable
rna-20211231_def.xml	Edgar Link	unprocessable
rna-20211231_lab.xml	Edgar Link	unprocessable
rna-20211231_pre.xml	Edgar Link	unprocessable
rna-ex1012_82.htm	Edgar Link	pending
rna-ex231_8.htm	Edgar Link	pending
rna-ex311_9.htm	Edgar Link	pending
rna-ex312_6.htm	Edgar Link	pending
rna-ex321_10.htm	Edgar Link	pending
rna-ex322_7.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNA
Avidity Biosciences, Inc. Stock $rna

2022 Q1 Form 10-K Financial Statement

#000156459022008049 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA Avidity Biosciences, Inc. Stock $rna

2022 Q1 Form 10-K Financial Statement

#000156459022008049 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNA
Avidity Biosciences, Inc. Stock $rna